Daclizumab  (Synonyms: Ro 24-7375)

Daclizumab (Ro 24-7375) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab inhibits effector T cell activation, regulatory T cell (Treg) expansion and survival, and activation-induced T-cell apoptosis. Daclizumab increases IL-2 bioavailability to bind to the intermediate-affinity IL-2R (IL-2R-IA), driving the expansion of anti-inflammatory CD56bright natural killer (NK) cells. Daclizumab can be used for multiple sclerosis and cancer research^[1].

Daclizumab (10 μg/mL) significantly inhibits late-phase CD40L expression on activated human CD4⁺T cells (both naive CD45RA⁺CD45RO^- and memory CD45RA^-CD45RO⁺ subsets) in PBMC cultures stimulated with anti-CD3/anti-CD28^[2].
Daclizumab (10 μg/mL) abolishes the restoration of CD40L expression by recombinant IL-2 (rIL-2), confirming that CD28-dependent CD40L expression is mediated via IL-2R signaling^[2].
Daclizumab (10 μg/mL) inhibits CD40L expression on Th1-polarized (cultured with rIL-12, rIL-2, anti-IL-4) and Th2-polarized (cultured with rIL-4, low-dose rIL-2) human CD4⁺ T cells after restimulation^[2].
Daclizumab (10 μg/mL, 48 h) inhibits CD40L expression on cells that divided once and reduces expression on non-dividing cells^[2].
Daclizumab (10 μg/mL, 48-72 h) markedly inhibits rIL-12-enhanced CD40L expression in PBMC cultures^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Daclizumab (100 μg/mouse, i.v., once weekly for 4 weeks on days 0, 7, 14, 21) exhibits significant anti-tumor efficacy in NOD/SCID mice bearing MET-1 human T-cell leukemia cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

144.24 kDa

152923-56-3

Liquid

Colorless to light yellow

[Daclizumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized IL-2R alpha/CD25 Protein, Human, HEK293, N-His, HY-P7215) can bind Daclizumab. The EC₅₀ for this effect is 16.81 ng/mL.
• 
  Flow Cytometry analysis of Romas cells labelling IL-2Ra/CD25 (red) with Daclizumab (anti-IL-2Ra/CD25) (HY-P108738). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.

• [1]. Cohan SL, et al. Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis. Biomedicines. 2019 Mar 11;7(1):18.  [Content Brief]

  [2]. Snyder JT, et al. Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production. Blood. 2007 Jun 15;109(12):5399-406.  [Content Brief]

  [3]. Zhang Z, et al. Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25. Blood. 2006 Aug 1;108(3):1007-12.  [Content Brief]